Introduction Leprosy, or Hansen’s disease, remains a cause of preventable disability. Early detection, treatment and prevention are key to reducing transmission. Post-exposure prophylaxis with single-dose rifampicin (SDR-PEP) reduces the risk of developing leprosy when administered to screened contacts of patients. This has been adopted in the WHO leprosy guidelines. The PEP4LEP study aims to determine the most effective and feasible method of screening people at risk of developing leprosy and administering chemoprophylaxis to contribute to interrupting transmission. Methods and analysis PEP4LEP is a cluster-randomised implementation trial comparing two interventions of integrated skin screening combined with SDR-PEP distribution to contacts of patients with leprosy in Ethiopia, Mozambique and Tanzania. One intervention is community-based, using skin camps to screen approximately 100 community contacts per leprosy patient, and to administer SDR-PEP when eligible. The other intervention is health centre-based, inviting household contacts of leprosy patients to be screened in a local health centre and subsequently receive SDR-PEP when eligible. The mobile health (mHealth) tool SkinApp will support health workers’ capacity in integrated skin screening. The effectiveness of both interventions will be compared by assessing the rate of patients with leprosy detected and case detection delay in months, as well as feasibility in terms of cost-effectiveness and acceptability. Ethics and dissemination Ethical approval was obtained from the national ethical committees of Ethiopia (MoSHE), Mozambique (CNBS) and Tanzania (NIMR/MoHCDEC). Study results will be published open access in peer-reviewed journals, providing evidence for the implementation of innovative leprosy screening methods and chemoprophylaxis to policymakers. Trial registration number NL7294 (NTR7503).
1 January 2023 in Revista da Sociedade Brasileira de Medicina Tropical
Leprosy is a neglected chronic infection caused by Mycobacterium leprae, that is curable. The magnitude of the disease and severity of the debilitation it causes renders leprosy a public health problem. This study aimed to analyze the endemic profile of leprosy in the Murrupula district and evaluate the socioeconomic, clinical, and serological profiles of leprosy contacts. A cross-sectional study of patients with leprosy diagnosed between 2013 and 2017 and their household and community contacts was conducted in Murrupula District, Nampula Province, Mozambique. Interviews, simplified dermatoneurological examinations, Mycobacterium leprae flow (ML Flow) tests, and Mitsuda tests were performed. Most of the leprosy cases were multibacillary. The patients had some degree of physical disability. ML Flow positivity was more common in household contacts of the patients diagnosed with leprosy and in community individuals who spontaneously presented for testing. In total, 17 patients were diagnosed with leprosy. This study revealed an active chain of transmission, hidden prevalence, and operational deficiencies in leprosy surveillance and care. The results suggest that the implementation of a public health policy for leprosy prevention and control in Nampula Province is necessary. In future, the possibility of expanding the policy to the entire country should be considered.
1 September 2018 in Revista Portuguesa de Clínica Geral
The African Journal of Primary Health & Family Medicine welcomes submissions that encourage scholarly exchange between family medicine and primary health care researchers and practitioners across Africa and the developing world, whilst providing a contextual and holistic view of family medicine as practiced across the continent.
Background Detection delay is defined as the period between onset of first signs and symptoms of leprosy and the time of diagnosis, comprising of a ‘patient delay’ and a ‘health-system delay’ and reliability refers to the consistency of a measure. Three types of consistency are considered: over time (test-retest reliability), across items (internal consistency), and across different researchers (interrater reliability). For the case detection delay (CDD) two are applicable: test-retest reliability and interrater reliability. Methods The study was conducted in Ethiopia, Mozambique and Tanzania. The CDD questionnaire was administered to 79 leprosy patients. One month later, another researcher re-administered the CDD questionnaire with these same patients. Interrater reliability was assessed using the intra class correlation coefficient (ICC). The test-retest reliability was assessed among 69 leprosy patients by determining the CDD at one month difference, both times using the same rater, and then we determined the reliability by looking at the Pearson correlation between the two sets of CDD data. Results Results from 79 leprosy patients show that, 3 (3.8%) were children under 15 years of age and 25 (31.6%) were women. Interrater reliability: the first interviews led to a mean CDD of 24.0 months (95% CI =17.1 - 30.9). The second interviews, also led to a mean CDD of 24.0 months (95% CI =17.7 - 30.3). For the test-retest reliability, the mean CDD of the first and second interviews were 16.5 (95% CI =13.6 - 19.5) and 16.9 (95% CI =13.8 - 20.1) respectively: the interrater reliability measured with ICC was 0.89 (95% CI of 0.84 - 0.93). Test-retest repeatability coefficient was 0.90 (p = 0.01). Conclusion The PEP4LEP CDD tool to determine the case detection delay of newly diagnosed leprosy patients, was validated in the three African countries showing that both test-retest and interrater reliability measurements demonstrated good reliability of the instrument.